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background
 
Current treatments for chronic hepatitis B are suboptimal. In the search for improved
therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivu-
dine, pegylated interferon alfa without lamivudine, and lamivudine alone for the treat-
ment of hepatitis B e antigen (HBeAg)–positive chronic hepatitis B.
 
methods
 
A total of 814 patients with HBeAg-positive chronic hepatitis B received either peginter-
feron alfa-2a (180 
 
µ
 
g once weekly) plus oral placebo, peginterferon alfa-2a plus lamiv-
udine (100 mg daily), or lamivudine alone. The majority of patients in the study were
Asian (87 percent). Most patients were infected with hepatitis B virus (HBV) genotype B
or C. Patients were treated for 48 weeks and followed for an additional 24 weeks.
 
results
 
After 24 weeks of follow-up, significantly more patients who received peginterferon
alfa-2a monotherapy or peginterferon alfa-2a plus lamivudine than those who received
lamivudine monotherapy had HBeAg seroconversion (32 percent vs. 19 percent
[P<0.001] and 27 percent vs. 19 percent [P=0.02], respectively) or HBV DNA levels be-
low 100,000 copies per milliliter (32 percent vs. 22 percent [P=0.01] and 34 percent vs.
22 percent [P=0.003], respectively). Sixteen patients receiving peginterferon alfa-2a
(alone or in combination) had hepatitis B surface antigen (HBsAg) seroconversion, as
compared with 0 in the group receiving lamivudine alone (P=0.001). The most com-
mon adverse events were those known to occur with therapies based on interferon alfa.
Serious adverse events occurred in 4 percent, 6 percent, and 2 percent of patients receiv-
ing peginterferon alfa-2a monotherapy, combination therapy, and lamivudine mono-
therapy, respectively. Two patients receiving lamivudine monotherapy had irreversible
liver failure after the cessation of treatment — one underwent liver transplantation, and
the other died.
 
conclusions
 
In patients with HBeAg-positive chronic hepatitis B, peginterferon alfa-2a offers supe-
rior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppres-
sion, and HBsAg seroconversion.
abstract
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ore than 400 million people
 
worldwide are chronically infected with
hepatitis B virus (HBV).
 
1
 
 Effective ther-
apy is necessary to prevent the progression of
chronic hepatitis B to cirrhosis, hepatocellular car-
cinoma, and death. Current consensus guidelines
from Asia, Europe, and the United States recom-
mend lamivudine, adefovir, or conventional inter-
feron alfa for the treatment of chronic hepatitis
B.
 
2-5
 
 Lamivudine and adefovir suppress HBV repli-
cation and result in an improvement in liver archi-
tecture on microscopical evaluation during thera-
py. However, rates of hepatitis B e antigen (HBeAg)
seroconversion, an end point that has been associ-
ated with improved long-term clinical out-
comes,
 
6,7
 
 are generally low with these agents.
 
8-10
 
Lamivudine and to a lesser extent adefovir are also
associated with drug resistance,
 
8,9,11,12
 
 which in-
creases with prolonged use.
 
12,13
 
 Although there
have been very few direct comparisons, rates of
HBeAg loss and seroconversion with conventional
interferon alfa seem to be slightly higher than the
rates with lamivudine or adefovir.
 
5
 
 Conflicting
data on the benefits of combining interferon-
based therapies and lamivudine
 
11,14,15
 
 indicate
that the role of combination therapy in the treat-
ment of chronic hepatitis B requires further clarifi-
cation.
Conventional interferon alfa has suboptimal
pharmacokinetics, resulting in an inconvenient
dosing schedule and fluctuating drug exposure.
Peginterferon alfa-2a, created by attaching a large,
branched, 40-kD polyethylene glycol molecule to
interferon alfa-2a,
 
16
 
 has better pharmacokinetics
than conventional interferon alfa. This allows for
once-weekly dosing, with effective serum concen-
trations maintained throughout the dosing inter-
val.
 
17
 
 Peginterferon alfa-2a, like conventional in-
terferon alfa, has a dual immunomodulatory and
antiviral mode of action. In a phase 2, proof-of-
concept study, peginterferon alfa-2a had better
clinical outcomes than did conventional interferon
alfa in patients with HBeAg-positive chronic hepa-
titis B.
 
18
 
The current study was designed to assess the ef-
ficacy and safety of three regimens in patients with
HBeAg-positive chronic hepatitis B: peginterferon
alfa-2a monotherapy, peginterferon alfa-2a plus la-
mivudine, and lamivudine monotherapy.
 
study design
 
This multicenter, randomized, partially double-
blind study was conducted at 67 sites in 16 countries
in Asia, Australasia, Europe, and North and South
America. The study was conducted in compliance
with the Declaration of Helsinki and with the prin-
ciples of Good Clinical Practice. All patients gave
written informed consent. 
Patients were randomly assigned in a 1:1:1 ratio
to receive 180 
 
µ
 
g of peginterferon alfa-2a (Pegasys,
Roche) once weekly plus oral placebo once daily,
180 
 
µ
 
g of peginterferon alfa-2a once weekly plus
100 mg of lamivudine (Epivir-HBV or Zeffix, Glaxo-
SmithKline) once daily, or 100 mg of lamivudine
once daily. Randomization was centralized and
stratified according to geographic region and ala-
nine aminotransferase levels. The study comprised
48 weeks of treatment and 24 weeks of treatment-
free follow-up.
The study was designed by the sponsor (Roche)
in collaboration with expert hepatologists. Clinical
data were collected by the Peginterferon Alfa-2a
HBeAg-Positive Chronic Hepatitis B Study Group.
The sponsor held the data and conducted the statis-
tical analyses. The principal authors had full access
to the data and vouch for the veracity and complete-
ness of the data and data analysis. All authors made
substantial contributions to the analysis and inter-
pretation of the data and the drafting or revising
of the manuscript. All authors approved the final
manuscript.
 
patients
 
Adults were eligible if they had been positive for
hepatitis B surface antigen (HBsAg) for at least
6 months, were negative for antibodies to HBsAg
(anti-HBs antibodies) and positive for HBeAg, had
an HBV DNA level of more than 500,000 copies per
milliliter, had a serum alanine aminotransferase lev-
el that was greater than 1 but less than or equal to
10 times the upper limit of the normal range, and
had had findings on a liver biopsy within the previ-
ous 12 months that were consistent with the pres-
ence of chronic hepatitis B. Exclusion criteria in-
cluded decompensated liver disease, a coexisting
serious medical or psychiatric illness, a neutrophil
count of less than 1500 per cubic millimeter, a plate-
m methods
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let count of less than 90,000 per cubic millimeter, a
serum creatinine level that was more than 1.5 times
the upper limit of the normal range, a history of al-
cohol or drug abuse within one year before entry,
and coinfection with hepatitis C or D virus or hu-
man immunodeficiency virus. Previous treatment
for chronic hepatitis B was permitted, but not with-
in the six months before the study.
 
efficacy measures
 
Efficacy analyses included all randomized patients
who received at least one dose of study medication.
The study had two predetermined primary measures
of efficacy assessed after 24 weeks of treatment-free
follow-up: HBeAg seroconversion (defined by the
loss of HBeAg and the presence of anti-HBe anti-
body) and suppression of HBV DNA to levels below
100,000 copies per milliliter. HBeAg and serum
HBV DNA were measured at a central laboratory
with the use of the AxSYM test (Abbott) and the
Cobas Amplicor HBV Monitor Test (Roche Diagnos-
tics), respectively.
Secondary efficacy measures assessed after 24
weeks of treatment-free follow-up included the
combined response (HBeAg seroconversion, the
normalization of alanine aminotransferase levels,
and the suppression of HBV DNA levels to below
100,000 copies per milliliter), HBsAg seroconver-
sion (defined by the loss of HBsAg and the presence
of anti-HBs antibody), and the histologic response.
A histologic response was defined as a reduction of
at least two points in the modified Histologic Activi-
ty Index score
 
19
 
 as compared with the pretreatment
score. Scores for this index can range from 0 to 24,
with inflammation graded from 0 (none) to 18 (se-
vere) and fibrosis graded from 0 (none) to 6 (cirrho-
sis). Biopsy samples were scored by an independent
histopathologist who was unaware of the timing of
the biopsy or the patient’s treatment assignment.
 
safety analysis
 
Measures of safety included adverse events, hema-
tologic measurements, clinical chemical measure-
ments, and vital signs. The severity of adverse events
was graded on a three-point scale (mild, moderate,
and severe), and causality was determined by the in-
vestigator. Safety was assessed at baseline; at weeks
1, 2, 4, 6, 8, and 12 and every six weeks thereafter
throughout treatment; and as appropriate during
follow-up. Safety analyses included all patients who
underwent randomization and received at least one
dose of study medication and who underwent at
least one safety assessment after the baseline as-
sessment.
 
resistance and genotypic analyses
 
HBV DNA was extracted from all available serum
samples from patients in the two lamivudine groups
at the end of treatment (week 48). Mutations in
the tyrosine, methionine, aspartate, and aspartate
(YMDD) motif of the HBV polymerase gene were
identified by means of the INNO-LiPA HBV DR as-
say (Innogenetics).
 
20 
 
Genotyping of HBV DNA was
performed at baseline on serum samples from all
patients by means of the INNO-LiPA HBV Genotyp-
ing assay (Innogenetics).
 
statistical analysis
 
A sample size of 231 patients per treatment group
provided the study with a statistical power of at least
80 percent at the 0.0125 level of significance, with
a two-sided test, to detect a difference in HBeAg se-
roconversion rates of 20 percent versus 34 percent
or HBV DNA response rates (suppression below
100,000 copies per milliliter) of 30 percent versus
45 percent. The sample size was increased to 250
patients to allow for withdrawals. An overall signif-
icance level of 0.025 was chosen because of the two
predetermined primary end points. This more strin-
gent overall significance level was adopted for reg-
ulatory reasons. For secondary efficacy measures,
the level of significance was set at 0.05.
The Cochran–Mantel–Haenszel test, stratified
according to geographic region and pretreatment
alanine aminotransferase level, was used to compare
differences in response rates between the treatment
groups. Only if the overall test of the treatment ef-
fect was significant were pairwise comparisons per-
formed. Fisher’s exact test was used when appro-
priate. For each treatment group, response rates
were computed with corresponding 95 percent con-
fidence intervals. No interim analyses were per-
formed.
Response rates were calculated for all patients
who received at least one dose of study drug, ac-
cording to the intention-to-treat principle. Patients
with missing values at week 72 were classified as
having no response.
 
characteristics of the patients
 
Of the 814 patients included in the analyses, 28 of
the 271 patients randomly assigned to receive
results
The New England Journal of Medicine 
Downloaded from nejm.org at UQ Library on March 28, 2017. For personal use only. No other uses without permission. 
 Copyright © 2005 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
352;26
 
www.nejm.org june 
 
30, 2005
 
peginterferon alfa-2
 
a
 
 in hb
 
e
 
a
 
g
 
-positive chronic hepatitis b
 
2685
 
peginterferon alfa-2a monotherapy, 25 of the 271
assigned to peginterferon alfa-2a plus lamivu-
dine, and 42 of the 272 assigned to lamivudine
monotherapy either did not complete treatment
or did not enter or complete the follow-up phase.
Baseline demographic and other characteristics
were similar among the three treatment groups
(Table 1).
 
* Percentages may not sum to 100 because of rounding.
† Race or ethnic group was generally assigned by the investigator, but in rare instances was clarified with the patient.
‡ The upper limit of the normal range is 30 IU per liter.
§ The presence or absence of bridging fibrosis and cirrhosis was assessed by local pathologists.
 
¶Log to the base 10 was used.
 
Table 1. Baseline Characteristics of the Patients.*
Characteristic
Peginterferon Alfa-2a
plus Placebo (N=271)
Peginterferon Alfa-2a
plus Lamivudine (N=271) Lamivudine (N=272)
 
Male sex — no. (%) 214 (79) 208 (77) 215 (79)
Race or ethnic group — no. (%)†
White 24 (9) 23 (8) 32 (12)
Asian 237 (87) 236 (87) 232 (85)
Black 4 (1) 4 (1) 3 (1)
Other 6 (2) 8 (3) 5 (2)
Age — yr
Mean ±SD 32.5±9.6 31.7±10.3 31.6±9.7
Median 31 29 30
Range 18–77 18–66 17–65
Weight — kg
Mean ±SD 66±13.0 66±14.8 67±14.4
Median 65 64 65
Range 35–128 41–135 40–160
Alanine aminotransferase — IU/liter‡
Mean ±SD 114.6±114.3 114.9±94.1 102.3±78.4
Median 84.0 81.8 82.1
Range 11.4–1266.0 13.2–642.0 5.9–462.1
HBV DNA — log copies/ml¶
Mean ±SD 9.9±2.1 10.1±1.9 10.1±2.0
Median 9.8 9.9 9.8
Range 4.4–16.1 3.1–17.9 3.0–16.0
Bridging fibrosis or cirrhosis — 
no. (%)§
49 (18) 40 (15) 47 (17)
Previous use of conventional 
interferon alfa — no. (%)
30 (11) 32 (12) 32 (12)
Previous use of lamivudine — no. (%) 31 (11) 24 (9) 42 (15)
Genotype distribution — no. (%)
A 23 (8) 18 (7) 15 (6)
B 76 (28) 82 (30) 73 (27)
C 162 (60) 156 (58) 162 (60)
D 9 (3) 11 (4) 17 (6)
E, F, or H 0 3 (1) 4 (1)
Mixed 1 (<1) 1 (<1) 1 (<1)
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At the end of treatment (week 48), the percentage of
patients with HBeAg seroconversion was highest
with peginterferon alfa-2a monotherapy (Table 2
and Fig. 1A). The overall HBeAg seroconversion
rates continued to rise during the entire study peri-
od in the two peginterferon alfa-2a groups but not
in the lamivudine monotherapy group; serorever-
sion (loss of anti-HBe antibody and re-expression of
HBeAg) was substantially less frequent with pegin-
terferon alfa-2a monotherapy (occurring in 13 of
72 patients, or 18 percent) and with combination
 
Table 2. Rates of HBeAg, Virologic, Biochemical, Combined, and Histologic Responses.*
Response End of Treatment (Week 48) End of Follow-up (Week 72)
 
Peginterferon
Alfa-2a plus
Placebo
(N=271)
Peginterferon
Alfa-2a plus
Lamivudine
(N=271)
Lamivudine
(N=272)
Peginterferon
Alfa-2a plus
Placebo
(N=271)
Peginterferon
Alfa-2a plus
Lamivudine
(N=271)
Lamivudine
(N=272)
 
HBeAg response
 
HBeAg seroconversion†
Patients — no. (%) 72 (27) 64 (24) 55 (20) 87 (32) 74 (27) 52 (19)
95% CI — % 21.4 to 32.2 18.7 to 29.1 15.6 to 25.5 26.6 to 38.0 22.1 to 33.0 14.6 to 24.3
P value <0.001 0.02
Odds ratio (95% CI)‡ 2.0 (1.3 to 3.0) 1.6 (1.1 to 2.4)
HBeAg loss
Patients — no. (%) 81 (30) 73 (27) 59 (22) 91 (34) 77 (28) 57 (21)
95% CI — % 24.5 to 35.7 21.7 to 32.6 16.9 to 27.1 28.0 to 39.5 23.1 to 34.2 16.3 to 26.3
P value <0.001 0.04
 
Virologic response
 
HBV DNA <100,000 copies/ml§
Patients — no. (%) 142 (52) 233 (86) 169 (62) 86 (32) 91 (34) 60 (22)
95% CI — % 46.3 to 58.5 81.3 to 89.9 56.1 to 67.9 26.2 to 37.6 28.0 to 39.5 17.3 to 27.5
P value 0.01 0.003
Odds ratio (95% CI)‡ 1.6 (1.1 to 2.4) 1.8 (1.2 to 2.6)
HBV DNA <400 copies/ml
Patients — no. (%) 68 (25) 186 (69) 108 (40) 39 (14) 37 (14) 14 (5)
95% CI — % 20.0 to 30.7 62.7 to 74.1 33.8 to 45.8 10.4 to 19.1 9.8 to 18.3 2.8 to 8.5
P value <0.001 <0.001
Change in HBV DNA
Total no. of patients 248 249 249 248 254 241
Mean log copies/ml ¡4.5 ¡7.2 ¡5.8 ¡2.4 ¡2.7 ¡1.9
95% CI — log copies/ml ¡4.1 to ¡4.9 ¡6.9 to ¡7.5 ¡5.4 to ¡6.1 ¡2.0 to ¡2.8 ¡2.2 to ¡3.1 ¡1.5 to ¡2.3
 
Biochemical response
 
Normalization of ALT
Patients — no. (%) 105 (39) 126 (46) 168 (62) 111 (41) 106 (39) 76 (28)
95% CI — % 32.9 to 44.8 40.4 to 52.6 55.7 to 67.6 35.0 to 47.1 33.3 to 45.2 22.7 to 33.7
P value 0.002 0.006
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therapy (14 of 64 patients, or 22 percent) than with
lamivudine monotherapy (23 of 55 patients, or 42
percent; P=0.005 and P=0.03, respectively, by Fish-
er’s exact test). After 24 weeks of follow-up (week
72), the percentage of patients with HBeAg sero-
conversion was significantly higher with peginter-
feron alfa-2a monotherapy (32 percent) and com-
bination therapy (27 percent) than with lamivudine
monotherapy (19 percent; P<0.001 and P=0.02, re-
spectively) (Table 2 and Fig. 2). At weeks 48 and 72,
rates of HBeAg loss closely reflected rates of HBeAg
seroconversion (Table 2).
HBeAg seroconversion rates in patients with and
without previous exposure to lamivudine or conven-
tional interferon were similar to rates in the overall
study population (Table 3). Additional stratified
analyses are detailed in Table 3.
 
virologic response
 
At week 48, the percentage of patients with sup-
pression of HBV DNA was highest with combina-
tion therapy (Table 2). This changed during follow-
up such that at week 72, suppression of HBV DNA
levels to less than 100,000 copies per milliliter oc-
curred in a significantly higher percentage of pa-
tients receiving peginterferon alfa-2a monotherapy
(32 percent) or peginterferon alfa-2a plus lamivu-
dine (34 percent) than in those receiving lamivudine
monotherapy (22 percent; P=0.01 and P=0.003,
respectively) (Table 2). Rates of suppression of HBV
 
* All P values are from the Cochran–Mantel–Haenszel test for pairwise comparison of each peginterferon alfa-2a group with the lamivudine 
monotherapy group at week 72. CI denotes confidence interval, and ALT alanine aminotransferase.
† P=0.003 for the overall test of treatment effect, and P=0.23 for the comparison between peginterferon alfa-2a plus placebo and peginterferon 
alfa-2a plus lamivudine.
‡ Odds ratios are given with 95 percent confidence intervals only for the two primary efficacy outcomes.
§ P=0.007 for the overall test of treatment effect, and P=0.65 for the comparison between peginterferon alfa-2a plus placebo and peginterferon 
alfa-2a plus lamivudine.
¶ Histologic response was defined as a reduction of at least two points in the modified Histology Activity Index score as compared with the 
pretreatment score. Scores for this index can range from 0 to 24, with inflammation graded from 0 (none) to 18 (severe) and fibrosis graded 
from 0 (none) to 6 (cirrhosis).
 
19
 
¿ Patients without paired biopsy samples were classified as having no response. P=0.23 for the overall test of treatment effect.
 
** Patients without paired biopsy samples were excluded. P=0.79 for the overall test of treatment effect.
 
Table 2. (Continued.)
Response End of Treatment (Week 48) End of Follow-up (Week 72)
 
Peginterferon
Alfa-2a plus
Placebo
(N=271)
Peginterferon
Alfa-2a plus
Lamivudine
(N=271)
Lamivudine
(N=272)
Peginterferon
Alfa-2a plus
Placebo
(N=271)
Peginterferon
Alfa-2a plus
Lamivudine
(N=271)
Lamivudine
(N=272)
 
Combined response
 
HBeAg seroconversion, normalization 
of ALT, and HBV DNA <100,000 
copies/ml
Patients — no. (%) 27 (10) 42 (15) 50 (18) 62 (23) 56 (21) 28 (10)
95% CI — % 6.7 to 14.2 11.4 to 20.4 14.0 to 23.5 18.0 to 28.3 16.0 to 26.0 7.0 to 14.5
P value <0.001 <0.001
 
Histologic response¶
 
All patients — no.¿ 271 271 272
Improved — no. of patients (%) 102 (38) 112 (41) 93 (34)
95% CI — % 31.8 to 43.7 35.4 to 47.4 28.6 to 40.2
Patients with paired biopsy samples 
— no.**
207 215 184
Improved — no. of patients (%) 102 (49) 112 (52) 93 (51)
95% CI — % 42.3 to 56.3 45.2 to 58.9 43.1 to 58.0
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Figure 1. Rates of HBeAg Seroconversion (Panel A) and HBV DNA Levels (Panel B), from Baseline to Week 72.
 
HBeAg seroconversion was defined by the loss of HBeAg and the presence of anti-HBe antibody. Log to the base 10 was used. The informa-
tion about the number of patients refers only to Panel B.
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DNA levels to less than 400 copies per milliliter at
week 72 were 14 percent with both peginterferon
alfa-2a monotherapy and peginterferon alfa-2a plus
lamivudine, and 5 percent with lamivudine alone
(P<0.001 for both comparisons with lamivudine
monotherapy). The patterns of HBV DNA levels
throughout the study are shown in Figure 1B. Rates
of normalization of alanine aminotransferase levels
and combined response at week 72 closely reflected
the virologic response rates (Table 2).
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g
 
 response
 
At week 72, HBsAg seroconversion was identified
in eight patients receiving peginterferon alfa-2a
monotherapy (three Asian and five white patients,
five with HBV genotype A and three with genotype
C) and in eight receiving peginterferon alfa-2a plus
lamivudine (five Asian and three white patients;
two with genotype A, one with genotype B, four with
genotype C, and one with genotype H). HBsAg se-
roconversion was not identified in any patients re-
ceiving lamivudine monotherapy. The differences
in HBsAg seroconversion between peginterferon
alfa-2a monotherapy and lamivudine monothera-
py, and between peginterferon alfa-2a plus lamivu-
dine and lamivudine monotherapy, were significant
(P=0.004 for both comparisons with lamivudine
monotherapy, by Fisher’s exact test).
 
histologic response
 
The rate of histologic response was similar among
the three treatment groups (Table 2). There was a
significant association between improved histolog-
ic activity and either HBeAg seroconversion, a viro-
logic response, or a biochemical response at week
72, regardless of the treatment group (P<0.001).
Among patients with paired biopsy samples, a his-
tologic response occurred in 133 of 179 patients
(74 percent) who had HBeAg seroconversion as
compared with 174 of 427 patients (41 percent) who
did not have HBeAg seroconversion (P<0.001 by the
log-likelihood ratio test).
 
alanine aminotransferase levels
 
Alanine aminotransferase elevations, defined as a
peak value at least five times as great as the baseline
value, occurred in 14 patients receiving peginter-
feron alfa-2a monotherapy (5 percent), 16 receiv-
ing combination therapy (6 percent), and 12 receiv-
ing lamivudine monotherapy (4 percent). Rates of
HBeAg seroconversion in these patients at week 72
were 43 percent, 38 percent, and 25 percent, respec-
tively (Table 3).
 
resistance
 
At week 48, YMDD mutations were detected in 69
of 254 patients receiving lamivudine monothera-
py (27 percent) and 9 of 256 patients receiving
peginterferon alfa-2a plus lamivudine (4 percent,
P<0.001).
 
safety
 
The rate of withdrawal from therapy was low in all
three groups (Table 4). The rates of adverse events
were similar in the peginterferon alfa-2a and com-
bination-therapy groups but were significantly less
frequent in the lamivudine-only group (P<0.001 for
the overall comparison). Among the three groups,
the incidence of adverse events was similar between
Asian and non-Asian patients (79 percent and 82
percent, respectively). The most common adverse
events were those known to occur with interferon
alfa therapy, including pyrexia, fatigue, headache,
and myalgia (Table 4).
Depression, which is a potential concern with
interferon-based therapy, was infrequent during the
study and was reported by 13 patients (5 percent)
receiving peginterferon alfa-2a monotherapy, 16 pa-
tients (6 percent) receiving peginterferon alfa-2a
plus lamivudine, and 4 patients (1 percent) receiving
lamivudine monotherapy.
 
Figure 2. Rates of HBeAg Seroconversion after 24 Weeks of Follow-up.
 
The percentage of patients with seroconversion in each group is shown at the 
top of the corresponding bar.
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* This group includes patients who had previously been treated with lamivudine, conventional interferon, and peginter-
feron only.
† This group includes only patients infected with HBV genotype A, B, C, or D.
 
‡ ULN denotes the upper limit of the normal range, which is 30 IU per liter.
 
Table 3. Effect of Baseline Factors and Alanine Aminotransferase Levels during Treatment on HBeAg Seroconversion 
Rates at Week 72.
Variable
Peginterferon Alfa-2a
plus Placebo
Peginterferon Alfa-2a
plus Lamivudine Lamivudine
 
no. of patients achieving HBeAg seroconversion/total no. of patients (%)
 
Overall study population 87/271 (32) 74/271 (27) 52/272 (19)
Patients with no previous anti-HBV therapy* 66/214 (31) 59/221 (27) 42/208 (20)
Patients with previous exposure 
to lamivudine
Yes 10/31  (32) 6/24  (25) 7/42  (17)
No 77/240 (32) 68/247 (28) 45/230 (20)
Patients with previous exposure to conven-
tional interferon
Yes 13/30  (43) 11/32  (34) 4/32  (12)
No 74/241 (31) 63/239 (26) 48/240 (20)
HBV genotype†
A 12/23  (52) 4/18  (22) 3/15  (20)
B 23/76  (30) 24/82  (29) 17/73  (23)
C 50/162 (31) 43/156 (28) 29/162 (18)
D 2/9  (22) 2/11  (18) 3/17  (18)
Baseline HBV DNA levels (log copies/ml)
≤9.07 37/70  (53) 20/56  (36) 24/78  (31)
>9.07–10.26 39/138 (28) 40/147 (27) 21/123 (17)
>10.26 11/63  (17) 14/68  (21) 7/71  (10)
Baseline alanine aminotransferase level 
(¬ULN)‡
≤2 27/92  (29) ‘ 19/93  (20) 19/96  (20)
>2 to 5 36/121 (30) 30/111 (27) 20/129 (16)
>5 24/58  (41) 25/67  (37) 13/47  (28)
Maximum alanine aminotransferase level 
during treatment (¬ULN)‡
≤5 39/149 (26) 35/150 (23) 33/177 (19)
>5 to 10 28/74  (38) 27/86  (31) 16/64  (25)
>10 20/48  (42) 12/35  (34) 3/31  (10)
Maximum alanine aminotransferase level 
during treatment (¬baseline value)
≤5 81/257 (32) 68/255 (27) 49/260 (19)
>5 6/14  (43) 6/16  (38) 3/12  (25)
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Thirty-three patients had serious adverse events
during treatment and up to eight weeks after thera-
py: 12 patients (4 percent) receiving peginterferon
alfa-2a monotherapy, 16 patients (6 percent) receiv-
ing peginterferon alfa-2a plus lamivudine, and 5 pa-
tients (2 percent) receiving lamivudine monotherapy
(Table 4). However, two patients receiving lamivu-
dine monotherapy, neither of whom had cirrhosis
or bridging fibrosis at baseline, had hepatic decom-
pensation after the cessation of treatment. One pa-
tient required liver transplantation and made a full
recovery, and one patient died.
Mean neutrophil and platelet counts were re-
duced during treatment with peginterferon alfa-2a
monotherapy and peginterferon alfa-2a plus lamiv-
udine, yet returned to baseline levels shortly after
treatment was stopped. Laboratory abnormalities
(alanine aminotransferase elevation, neutropenia,
and thrombocytopenia) were the most common rea-
son for dose modification (Table 4).
We found that peginterferon alfa-2a alone or in
combination with lamivudine resulted in higher
rates of sustained HBeAg, HBsAg, virologic, and
biochemical response among patients with HBeAg-
positive chronic hepatitis B than did lamivudine
alone. HBeAg seroconversion is a key objective of
therapy for HBeAg-positive chronic hepatitis B,
since it is associated with improved long-term clin-
ical outcomes, such as histologic improvement and
increased complication-free and overall survival.
 
6,7
 
In this study of patients, predominantly of Asian
origin, who had previously been considered to have
difficult-to-treat chronic hepatitis B,
 
21
 
 HBeAg se-
roconversion rates were significantly higher after
24 weeks of treatment-free follow-up in patients
receiving peginterferon alfa-2a alone or in combi-
nation with lamivudine than in those receiving la-
mivudine alone. Previous exposure to lamivudine
did not affect the overall rates of HBeAg serocon-
version. In accordance with previous findings with
interferon alfa therapy,
 
22
 
 marked elevations in ala-
nine aminotransferase levels were more frequently
associated with HBeAg response in patients receiv-
ing peginterferon alfa-2a alone or in combination
with lamivudine than in those receiving lamivudine
alone.
At present, it is not clear whether viral genotype
is a predictor of treatment response in chronic hep-
atitis B, as it is in chronic hepatitis C. Responses to
nucleoside or nucleotide analogues are generally
consistent among all genotypes,
 
23,24
 
 whereas high-
er responses to interferon alfa have been reported
for HBV genotype A than for genotype D and for ge-
notype B than for genotype C.
 
25
 
 The results of our
study indicate that HBeAg seroconversion was gen-
erally consistent across all genotypes. However, a
recent study of peginterferon alfa-2b
 
26
 
 reported a
higher HBeAg seroconversion rate for genotype A.
This trend was also observed in our study in the pa-
tients receiving peginterferon alfa-2a monotherapy.
However, in our study, the number of patients in-
fected with genotype A was very low.
Previous studies have shown that HBV DNA
suppression is associated with HBeAg serocon-
version.
 
8,10,27
 
 At week 48 of our study, viral suppres-
sion was higher in patients receiving lamivudine
monotherapy than in those receiving peginterferon
alfa-2a monotherapy. However, despite this more
potent suppression of HBV DNA with lamivudine,
rates of HBeAg seroconversion at the end of treat-
ment and after follow-up were highest with pegin-
terferon alfa-2a monotherapy. These data indicate
that a separate and probably immunomodulatory
component influences HBeAg seroconversion with
peginterferon alfa-2a. Similarly, among patients re-
ceiving peginterferon alfa-2a monotherapy or peg-
interferon alfa-2a plus lamivudine, who presumably
had equivalent immunomodulation related to peg-
interferon alfa-2a, the increased antiviral activity in
the group receiving combination therapy did not
improve HBeAg seroconversion rates. Significantly
fewer patients receiving combination therapy had
YMDD mutants at the end of treatment than did pa-
tients receiving lamivudine alone. This suggests that
more profound HBV DNA suppression, such as that
seen during treatment with peginterferon alfa-2a
plus lamivudine, leads to a lower incidence of la-
mivudine resistance, a finding that concurs with
previous studies of HBV.
 
28,29
 
HBsAg loss or seroconversion after therapy is
considered the ultimate therapeutic goal of anti-
HBV therapy, since it is associated with positive
long-term clinical outcomes.
 
2,4,5,30
 
 In this study,
HBsAg seroconversion was identified in 8 of 473
Asian patients (2 percent) and 8 of 47 white pa-
tients (17 percent) receiving peginterferon alfa-2a
alone or in combination with lamivudine, as com-
pared with none receiving lamivudine alone. These
HBsAg seroconversion rates with peginterferon
discussion
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alfa-2a compare favorably with rates of HBsAg re-
sponse within 12 months of the cessation of treat-
ment that were shown in studies of conventional
interferon in Asian
 
31-33
 
 and white
 
7,30
 
 patients.
No statistically significant differences in efficacy
were observed between the groups receiving peg-
interferon alfa-2a monotherapy and peginterfer-
on alfa-2a plus lamivudine after 24 weeks of fol-
low-up, a finding that concurs with a recent study of
patients with HBeAg-negative chronic hepatitis B.
 
29
 
However, these results do not categorically rule out
the possibility that combination therapy, including
sequential therapy, may provide clinically relevant
benefits.
The tolerability and safety profiles of peginter-
feron alfa-2a monotherapy and peginterferon alfa-
2a plus lamivudine were similar to those reported in
patients with HBeAg-negative chronic hepatitis B,
and there were no unexpected adverse effects.
 
29
 
 The
safety profile of peginterferon alfa-2a in this study
also compares favorably with the profiles described
in previous studies of conventional interferon alfa in
HBeAg-positive chronic hepatitis B.
 
11,18
 
 As antici-
pated, peginterferon alfa-2a alone or in combina-
tion with lamivudine was not tolerated as well as
lamivudine monotherapy. However, the rate of with-
drawal from peginterferon alfa-2a therapy was less
than 5 percent.
Depression was reported in 5 percent of patients
receiving peginterferon alfa-2a in this study. This
incidence is substantially lower than that observed
among patients with chronic hepatitis C (16 to 20
percent).
 
34,35
 
 This finding concurs with data from
a recent study of peginterferon alfa-2a in HBeAg-
negative chronic hepatitis B.
 
29
 
In conclusion, the results of this large, multina-
tional study show that peginterferon alfa-2a pro-
vides significantly improved efficacy over lamivu-
dine in the treatment of HBeAg-positive chronic
hepatitis B. Improvement in sustained HBeAg and
HBsAg seroconversion rates, as well as sustained
virologic and biochemical response rates, indicate
that peginterferon alfa-2a offers a therapeutic ad-
vantage over available treatments for chronic hepa-
titis B. The ability to achieve HBeAg and HBsAg
seroconversion after a defined period of peginter-
 
Table 4. Incidence of Discontinuation of Treatment, Dose Modification, and Adverse Events.*
Variable
Peginterferon Alfa-2a
plus Placebo 
(N=271)
Peginterferon Alfa-2a
plus Lamivudine 
(N=271)
Lamivudine 
(N=272)
 
number of patients (percent)
 
Discontinuation
 
For safety reasons† 8 (3) 12 (4) 2 (1)
For other reasons‡ 9 (3) 6 (2) 12 (4)
 
Dose modification
 
§
Total 124 (46) 127 (47) —
Adverse event 20 (7) 23 (8) —
Laboratory abnormality 99 (37) 102 (38) —
Dose missed or dosage error 25 (9) 20 (7) —
Other 2 (1) 2 (1) —
 
Adverse events
 
≥1 Reported serious adverse event (weeks 0 to 56)¶ 12 (4) 16 (6) 5 (2)
Deaths
Weeks 0 to 56 0 3 (1)¿ 0
Weeks 57 to 72 0 0 1 (<1)**
≥1 Reported adverse event (weeks 0 to 56)†† 240 (89) 240 (89) 152 (56)
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* Values are based on all randomized patients who received at least one dose of study medication and had at least one safety 
assessment after baseline. Dashes indicate no dose modifications in the group receiving lamivudine monotherapy.
† P=0.03 for the overall test of treatment effect. P=0.06 for the comparison between peginterferon alfa-2a plus placebo 
and lamivudine alone, and P=0.01 for the comparison between peginterferon alfa-2a plus lamivudine and lamivudine 
alone.
‡ P=0.36 for the overall test of treatment effect.
§ Some patients who required a dose modification had both an adverse event and a laboratory abnormality. Laboratory 
abnormalities include alanine aminotransferase elevation, neutropenia, and thrombocytopenia. Other includes circum-
stances related to patient compliance.
¶ A serious adverse event was one that presented a clinically significant hazard or resulted in a contraindication, side ef-
fect, or precaution. P=0.05 for the overall test of treatment effect, P=0.09 for the comparison between peginterferon 
alfa-2a plus placebo and lamivudine alone, and P=0.01 for the comparison between peginterferon alfa-2a plus lamivu-
dine and lamivudine alone.
¿ All three deaths were accidental and were considered by the investigators to be unrelated to the study medication.
** Life-threatening hepatic encephalopathy developed in this patient, which was considered by the investigator to be relat-
ed to discontinuation of lamivudine treatment.
††P<0.001 for the overall test of treatment effect, P<0.001 for the comparison between peginterferon alfa-2a plus placebo 
and lamivudine alone, and P<0.001 for the comparison between peginterferon alfa-2a plus lamivudine and lamivudine 
alone.
‡‡Patients may have had more than one adverse event. The adverse events listed are those reported by at least 5 percent 
of patients in any treatment group.
Table 4. (Continued.)
Variable
Peginterferon Alfa-2a
plus Placebo 
(N=271)
Peginterferon Alfa-2a
plus Lamivudine 
(N=271)
Lamivudine 
(N=272)
number of patients (percent)
Adverse events (continued)
Most common adverse events (weeks 0 to 56)‡‡
Pyrexia 133 (49) 148 (55) 12 (4)
Fatigue 108 (40) 101 (37) 37 (14)
Headache 76 (28) 81 (30) 27 (10)
Myalgia 70 (26) 77 (28) 8 (3)
Alopecia 55 (20) 78 (29) 6 (2)
Decreased appetite 40 (15) 34 (13) 5 (2)
Rash 27 (10) 22 (8) 10 (4)
Pruritus 26 (10) 26 (10) 5 (2)
Dizziness 25 (9) 32 (12) 11 (4)
Diarrhea 25 (9) 26 (10) 9 (3)
Nausea 24 (9) 27 (10) 6 (2)
Injection-site reaction 24 (9) 15 (6) 0
Arthralgia 24 (9) 24 (9) 7 (3)
Upper respiratory tract infection 21 (8) 15 (6) 29 (11)
Insomnia 20 (7) 23 (8) 10 (4)
Rigors 19 (7) 27 (10) 0
Upper abdominal pain 19 (7) 14 (5) 20 (7)
Sore throat 15 (6) 21 (8) 19 (7)
Gingival bleeding 15 (6) 15 (6) 1 (<1)
Cough 14 (5) 19 (7) 10 (4)
Dyspepsia 14 (5) 6 (2) 9 (3)
Depression 13 (5) 16 (6) 4 (1)
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feron alfa-2a therapy supports the use of peginter-
feron alfa-2a as a first-line therapy for patients with
HBeAg-positive chronic hepatitis B.
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